Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Ganaxolone (Ztalmy, Orion and Marinus) is indicated for the 'adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 ...

Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) for this ...

This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee, which is a standing advisory committee of NICE. Committee members are asked to ...